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Induction chemoradiation and complete surgical resection provide 
better survival for non-small-cell lung carcinomas of the superior 
sulcus
Tagawa, Tetsuzo; Yamazaki, Koji; Okamoto, Tatsuro; Kometani, 
Takuro; Wataya, Hiroshi; Seto, Takashi; Ichinose, Yukito 
National Kyushu Cancer Center, Fukuoka, Japan
Background: Non-small-cell lung carcinomas (NSCLC) of the 
superior sulcus are particularly challenging to treat because they often 
involve the spine, brachial plexus and subclavian vessels. Recently, 
combined modality therapy including induction chemoradiotherapy fol-
lowed by resection has improved outcomes of this tumor. 
Methods: We retrospectively analyzed the records of 61 patients with 
the superior sulcus NSCLC without distant metastasis at presentation 
who were treated initially in our institution between 1982 and 2007.
Results: Median age at presentation was 60 years (range 34 to 80 
years) and 53 patients (87%) were men. 33 patients (54%) had clinical 
T3 tumors while 28 (46%) had clinical T4 tumors. As to the nodal 
status judged by computed tomography of the chest, 36 (59%), 7 
(12%), 13 (21%) and 5 (8%) patients had clinical N0, N1, N2 and N3 
nodal status, respectively. Mediastinoscopy were not performed in all 
patients. The histologic subtype was adenocarcinoma in 28 patients 
(46%), squamous cell carcinoma in 20 patients (33%), large cell car-
cinoma in 9 patients (15%), and other subtypes in 4 patients (6%). As 
the initial therapy, 33 patients (54%) received concurrent chemoradio-
therapy, 19 patients (31%) received surgery, 8 patients (13%) received 
radiotherapy, and 1 patient received chemotherapy. Of the 33 patients 
who received concurrent chemoradiotherapy, mean total radiation 
dose was 50.0Gy, 32 patients received platinum based combination 
chemotherapy and 28 patients received surgery subsequently. Four 
patients received surgery after radiotherapy. The operations performed 
included 48 lobectomies and 2 penumonectomies and 1 exploratory 
thoracotomy. Combined chest wall resection was performed in 47 pa-
tients. Complete surgical resection was performed in 48 patients (79%). 
The postoperative mortality rate was 2.0% (1/51). Median follow-up 
time of all patients was 35 months. Overall 5-year survival rate was 
53.0%. The median survival time was 72 months. By univariate analy-
sis, chemoradiotherapy and complete resection signiﬁcantly affected 
overall survival. Five-year survival rate was 61.1% in 33 patients who 
received chemoradiotherapy and 61.7% in 47 patients who received 
complete resection. The median survival time was not reached in pa-
tients who received chemoradiotherapy and was 107 months in patients 
who received complete resection. Multivariate analysis identiﬁed that 
complete resection was the only factor signiﬁcantly associated with 
overall survival. The clinical T status and clinical N status did not cor-
relate with survival. 
Conclusions: The use of concurrent chemoradiation induction therapy 
may downstage tumors, enhance the ability to obtain a complete surgi-
cal resection, and prolong survival even in T4 or N2-3 patients.
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Phase II study of TS-1(S) plus cisplatin(P) with concurrent thoracic 
radiotherapy for unresectable stage III non-small cell lung cancer 
(NSCLC)
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Background: Although combined chemoradiotherapy is the standard 
of care in stage III NSCLC, the optimal chemotherapy regimen is 
not established. S-1, a fourth-generation oral ﬂuoropyrimidine is an 
active new agent for NSCLC and the combination with cisplatin has a 
favorable toxicity proﬁle. The objective of this study was to evaluate 
feasibility and efﬁcacy of S plus P with concurrent radiation for unre-
sectable stage III NSCLC.
Methods: Patients with histologically or cytologically conﬁrmed 
NSCLC, 20 to 75 years in age, performance status 0-1, with no prior 
chemotherapy were eligible for the study. Patients were treated with P 
(60 mg/m2 on day 1) and S (orally at 40 mg/m2/dose bid (80 mg/2/d), 
on days 1 to 14) repeated every 3-4 weeks for 4 cycles and TRT (60 
Gy/30fr over 6 weeks starting on day 2). The primary endpoint was the 
response rate (RR), and planned sample size for this phase II study was 
28 patients (Simon’s two-stage minimax design, P0=70%, P1=90%, α 
=0.1, β = 0.1).
Results: Of 28 patients enrolled between August 2005 and October 
2006, 28 were evaluable. There were 24 males and 4 females, median 
age of 63 (range 40-74) and 11 IIIA and 17 IIIB. Chemoradiotherapy 
was well tolerated; 2 cycles of SP and 60Gy of TRT were administered 
in all patients and 24 (86%) patients received 4 cycles of SP. During 
concurrent chemoradiotherapy, grade 3 toxicities were neutropenia (8 
pts), leukopenia (6 pts), fatigue (6 pts), anorexia (5 pts), febrile neutro-
penia (4 pts) and, esophagitis (4 pts). Only one grade 4 leukopenia were 
observed. During consolidation therapy, grade 3-4 neutropenia, anemia, 
esophagitis, and pneumonitis were developed in 4, 1, 1 and 2 patients, 
respectively. No toxic deaths have occurred.Overall RR was 85.7% 
(95%CI: 79.1-98.7%) with 4 SDs and 24 PRs. The median progression-
free survival and median survival is not mature enough to estimate as 
only 4 progression and no deaths have occurred.
Conclusions: This chemoradiotherapy regimen produced promising 
response rate in patients with stage III NSCLC and it seems to be well-
tolerated.
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A phase II study of daily gefitinib plus weekly paclitaxel (GP) in 
Taiwanese non-small cell lung cancer (NSCLC) patients who failed 
gefitinib (G) or both G monotherapy and taxane (T) treatment
Tsai, Chun-Ming; Lai, Chun-Liang; Chiu, Chao-Hua; Liou, Jia-Ling; 
Chang, Kuo-Ting 
Section of Thoracic Oncology, Chest Department, Taipei Veterans Gen. 
Hospital, Taipei, Taiwan
Background: G, an epidermal growth factor receptor (EGFR) tyrosine 
kinase inhibitor, is an active agent in subgroup of NSCLC patients (pts) 
